|[July 10, 2014]
LifeMap Sciences, a Subsidiary of BioTime, Announces Release of GeneCards® Version 3.12 and the Introduction of GeneCards PlusTM
ALAMEDA, Calif. --(Business Wire)--
LifeMap Sciences, Inc., a subsidiary of BioTime, Inc., announced today
the release of GeneCards® Version 3.12. The new release is
available at www.genecards.org.
GeneCards® is an online database that provides comprehensive
information on all known human genes. The new release features the
launch of LifeMap Science's Premium Services platform, which offers our
strong user base access to GeneCards Plus' powerful tools and
advanced functionality integrated with the LifeMap Integrated
Knowledgebase, which includes GeneCards®, MalaCards and LifeMap
GeneCards® 3.12 introduces GeneCards PlusTM,
a suite of productivity tools for registered members. The new features
- A powerful and easy-to-use gene
set analysis tool, which integrates proprietary gene expression
data from LifeMap
Discovery®, and significantly enriched gene associations to
disorders, pathways, GO terms and compounds from GeneCards®
- A revamped user interface for GeneALaCart, GeneCards' batch query
tool, with the capability to receive a complete quota's worth of gene
- A new Next
Generation Sequencing Variant Selection facility, which finds and
ranks genes related to user-specified phenotype terms.
- A new Pathways-Centric site, which unifies human biological pathways
consolidated from 12 sources into SuperPaths, based on gene-content
More information about GeneCards Plus is available at http://www.genecards.org/index.php?path=/HTML/page/aboutGeneCardsPlus.
Additional features of the new GeneCards® release include:
More than 169,000 gene entries, including the world's largest
collection of more than ~123,300 non-protein-coding RNAs.
Protein subcellular localization images with evidence and confidence
scores from the COMPARTMENTS subcellular localization database.
Transcription Factor Regulatory Elements motif viewer and Consensus
sequence from HOMER.
Enhanced post-translational modification with newly introduced
ubiquitination and glycosylation sites from NextProt.
Links to CYP alleles and their associated effects from the Human
Cytochrome P450 Allele Nomenclature Database.
Enhanced proteomics via the addition of 23 protein expression tissues
Addition of journal name to article listings in the Publications
Improved presentation of signaling molecules and growth factors from
"Our GeneCards development team is proud to see the emergence of two new
and exciting affiliated tools. VarElect will utilize the most
comprehensive gene information present inside GeneCards to highlight the
best candidates for a disease's causative gene. And PathCards, with its
featured SuperPaths, will provide users with a one-stop source for
pathways, their contained genes and their mutual relationships," said
Professor Doron Lancet, Ph.D., Head of the Crown Human Genome Center at
the Weizmann Institute of Science.
"We are excited to introduce GeneCards Plus, now part of the LifeMap
Integrated Knowledgebase," stated Yaron Guan-Golan, Chief Marketing
Officer of LifeMap Sciences. "GeneCards Plus offers GeneCards users
access to our Premium Services platform, which enables researchers to
leverage all three of our databases to further their research."
About LifeMap Sciences, Inc.
LifeMap Sciences' (www.lifemapsc.com)
core technology and business is based on its Integrated Biomedical
Knowledgebase and discovery platform for biomedical research, which
the leading human gene database; LifeMap
Discovery®, the database of embryonic development, stem cell
research and regenerative medicine; and MalaCards,
the human disease database. LifeMap's products are used in many
institutions including academia, research hospitals, patent offices, and
leading biotechnology and pharmaceutical companies. In addition to its
currently marketed products, LifeMap is pursuing several new internet
and informatics products which leverage its existing products and their
large user base.
LifeMap Sciences holds the exclusive worldwide license to market GeneCards®
and MalaCards from Yeda Research and Development Company
Ltd., the commercial arm of the Weizmann Institute of Science. As one of
the leading suppliers of online databases for information on genes,
cells, and diseases, LifeMap Sciences intends to continually improve the
quality of its products as well as extend its applications to the
general public through future consumer product offerings in the field of
mobile health by its subsidiary LifeMap Solutions, Inc.
About the Weizmann Institute of Science and GeneCards
The Weizmann Institute of Science in Rehovot, Israel, is one of the
world's top-ranking multidisciplinary research institutions. Noted for
its wide-ranging exploration of the natural and exact sciences, the
Institute is home to scientists, postdoctoral fellows, Ph.D. and M.Sc.
students, and scientific, technical and administrative staff. In
addition, visiting scientists and their families - over 500 from 35
countries are regularly hosted at the Institute. The Institute was
founded in 1934 following a donation to Dr. Chaim Weizmann, a noted
biochemist and biotechnologist, who envisioned the establishment of a
world-class scientific research center in Israel, and later also became
the first President of the State of Israel. Weizmann Institute's
Feinberg Graduate School, established in 1958, has 1000 M.Sc. and Ph.D.
students enrolled in studies covering the Institute's five faculties:
Biochemistry, Biology, Chemistry, Physics, and Mathematics and Computer
Science. The Institute's technology transfer arm, Yeda Research and
Development Co. was the first company of its kind in Israel, and is
currently one of the most successful worldwide. Institute research
efforts include the search for new ways of fighting disease and hunger,
examining leading questions in mathematics and computer science, probing
the physics of matter and the universe, creating novel materials and
developing new strategies for protecting the environment. Particular
excellence in bioinformatics and systems biology is manifested, among
others, in the GeneCards project, initiated in 1996, under the
leadership of Prof. Doron Lancet of the Dept. of Molecular Genetics,
Head of the Crown Human Genome Center and The Ralph D. and Lois R.
Silver Professor of Human Genomics. A team of 10 led by Marilyn Safran
continuously innovates and keeps GeneCards as a world-top human gene
compendium, automatically mining and integrating 100 worldwide web
BioTime is a biotechnology company engaged in research and product
development in the field of regenerative medicine. Regenerative medicine
refers to therapies based on stem cell technology that are designed to
rebuild cell and tissue function lost due to degenerative disease or
injury. BioTime's focus is on pluripotent stem cell technology based on
human embryonic stem ("hES") cells and induced pluripotent stem ("iPS")
cells. hES and iPS cells provide a means of manufacturing every cell
type in the human body and therefore show considerable promise for the
development of a number of new therapeutic products. BioTime's
therapeutic and research products include a wide array of proprietary PureStem®
hydrogels, culture media, and differentiation kits. BioTime is
developing Renevia™ (a HyStem® product) as a
biocompatible, implantable hyaluronan and collagen-based matrix for cell
delivery in human clinical applications, and is planning to initiate a
pivotal clinical trial around Renevia™, in 2014. In addition,
BioTime has developed Hextend®,
a blood plasma volume expander for use in surgery, emergency trauma
treatment and other applications. Hextend® is manufactured and
distributed in the U.S. by Hospira, Inc. and in South Korea by CJ
HealthCare Corporation, under exclusive licensing agreements.
BioTime is also developing stem cell and other products for research,
therapeutic, and diagnostic use through its subsidiaries:
Biotherapeutics, Inc. is developing pluripotent stem-cell
based therapies in neurology and oncology, including AST-OPC1
oligodendrocyte progenitor cells in spinal cord injury, multiple
sclerosis and stroke, and AST-VAC2, an allogeneic dendritic cell-based
BioTime Asia, Ltd., a Hong Kong
company, may offer and sell products for research use for BioTime's
ESI (News - Alert) BIO Division.
Cure Neurosciences Ltd. is an Israel-based biotechnology
company focused on developing stem cell-based therapies for retinal
and neurological disorders, including the development of retinal
pigment epithelial cells for the treatment of macular degeneration,
and treatments for multiple sclerosis.
BIO is the research and product marketing division of BioTime,
providing stem cell researchers with products and technologies to
enable them to translate their work into the clinic, including PureStem®
progenitors and HyStem® hydrogels.
Sciences, Inc. markets, sells, and distributes GeneCards®,
the leading human gene database, as part of an integrated database
suite that also includes the LifeMap
Discovery® database of embryonic development, stem cell
research, and regenerative medicine, and MalaCards,
the human disease database.
Solutions, Inc. is a subsidiary of LifeMap Sciences focused on
developing mobile health (mHealth) products.
Corporation is developing products and technologies to diagnose and
treat cancer, including PanC-Dx™, with three clinical trials
Corporation is developing therapies to treat orthopedic disorders,
diseases and injuries.
Therapeutics, Inc. is developing therapies to treat a variety
of cardiovascular and related ischemic disorders, as well as products
for research using cell reprogramming technology.
BioTime stock is traded on the NYSE MKT, ticker BTX. For more
information, please visit www.biotimeinc.com
or connect with the company on Twitter,
Statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for BioTime and its subsidiaries, along with
other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management constitute forward-looking
statements. Any statements that are not historical fact (including, but
not limited to statements that contain words such as "will," "believes,"
"plans," "anticipates," "expects," "estimates") should also be
considered to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or regulatory
approvals, need and ability to obtain future capital, and maintenance of
intellectual property rights. Actual results may differ materially from
the results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that affect the
businesses of BioTime and its subsidiaries, particularly those mentioned
in the cautionary statements found in BioTime's Securities and Exchange
Commission filings. BioTime disclaim any intent or obligation to update
these forward-looking statements.
[ Back To TMCnet.com's Homepage ]